What are gene therapies? What are some recent advancement in gene therapy? How does development in gene therapy differ from common drugs?

Today's episode is slightly different from the previous ones. It is the first time that TWO brilliant biostatisticians share their insight in the same episode! Avery McIntosh and Alex Sverdlov will answer all the questions about gene therapy for you!

Dr. McIntosh is currently engaged in drug development for rare diseases at Pfizer, where he leads a team of statisticians working across different study phases and a range of drug types and disease areas. Meanwhile, Dr. Sverdlov serves as the Neuroscience Disease Area statistical lead at Novartis, where he focuses on methodological research and the application of innovative statistical methods in drug development.

Other than an interesting gene therapy 101 that Avery and Alex gave in this episode, they also recently co-published a book called "Development of gene therapies: strategic, scientific, regulatory, and Access considerations", which is now available. I will put the link of the book in the show notes and please check it out if you are either a long term enthusiast of gene therapy or if you start to think gene therapy is interesting after listening to this episode. Let dive into this episode and see what Avery and Alex have shared with us.

You can find Avery and Alex's new book here.

Please visit our website https://biostatisticspodcast.github.io/ for the latest updates and transcripts of the published episodes.
If you have any comments, feedback, or suggestions, feel free to email us via biostatisticspodcast@gmail.com or DM us on Twitter @BiostatsPodcast